These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31763491)

  • 1. Rationale and design of an international randomized placebo-controlled trial of a 36-ingredient micronutrient supplement for children with ADHD and irritable mood: The Micronutrients for ADHD in Youth (MADDY) study.
    Johnstone JM; Leung B; Gracious B; Perez L; Tost G; Savoy A; Hatsu I; Hughes A; Bruton A; Arnold LE
    Contemp Clin Trials Commun; 2019 Dec; 16():100478. PubMed ID: 31763491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micronutrients for Attention-Deficit/Hyperactivity Disorder in Youths: A Placebo-Controlled Randomized Clinical Trial.
    Johnstone JM; Hatsu I; Tost G; Srikanth P; Eiterman LP; Bruton AM; Ast HK; Robinette LM; Stern MM; Millington EG; Gracious BL; Hughes AJ; Leung BMY; Arnold LE
    J Am Acad Child Adolesc Psychiatry; 2022 May; 61(5):647-661. PubMed ID: 34303786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Executive function in children with disruptive mood dysregulation disorder compared to attention-deficit/hyperactivity disorder and oppositional defiant disorder, and in children with different irritability levels.
    Brænden A; Coldevin M; Zeiner P; Stubberud J; Melinder A
    Eur Child Adolesc Psychiatry; 2024 Jan; 33(1):115-125. PubMed ID: 36680626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomized, placebo-controlled trial of a computer-based Interpretation Bias Training for youth with severe irritability: a study protocol.
    Haller SP; Stoddard J; MacGillivray C; Stiles K; Perhamus G; Penton-Voak IS; Bar-Haim Y; Munafò MR; Brotman MA
    Trials; 2018 Nov; 19(1):626. PubMed ID: 30428909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paediatric adverse event rating scale: a measure of safety or efficacy? Novel analysis from the MADDY study.
    Leung BMY; Srikanth P; Gracious B; Hatsu IE; Tost G; Conrad V; Johnstone JM; Arnold LE
    Curr Med Res Opin; 2022 Sep; 38(9):1595-1602. PubMed ID: 35770861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.
    Winters DE; Fukui S; Leibenluft E; Hulvershorn LA
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):298-305. PubMed ID: 29708762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin-mineral treatment improves aggression and emotional regulation in children with ADHD: a fully blinded, randomized, placebo-controlled trial.
    Rucklidge JJ; Eggleston MJF; Johnstone JM; Darling K; Frampton CM
    J Child Psychol Psychiatry; 2018 Mar; 59(3):232-246. PubMed ID: 28967099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.
    Pan PY; Fu AT; Yeh CB
    J Child Adolesc Psychopharmacol; 2018 Dec; 28(10):682-689. PubMed ID: 30148656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Composite Primary Outcome Score for Children with Attention-Deficit/Hyperactivity Disorder and Emotional Dysregulation.
    Johnstone JM; Leung BMY; Srikanth P; Hatsu I; Perez L; Gracious B; Tost G; Aman MG; Gadow KD; Findling RL; Bukstein O; Arnold LE
    J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):166-172. PubMed ID: 32101469
    [No Abstract]   [Full Text] [Related]  

  • 10. Mineral-Vitamin Treatment Associated with Remission in Attention-Deficit/Hyperactivity Disorder Symptoms and Related Problems: 1-Year Naturalistic Outcomes of a 10-Week Randomized Placebo-Controlled Trial.
    Darling KA; Eggleston MJF; Retallick-Brown H; Rucklidge JJ
    J Child Adolesc Psychopharmacol; 2019 Nov; 29(9):688-704. PubMed ID: 31343273
    [No Abstract]   [Full Text] [Related]  

  • 11. Dosages of Nutrient Supplements and Potential Long-Term Toxicity in Attention-Deficit/Hyperactivity Disorder Micronutrient Study.
    Elmrayed S
    J Am Acad Child Adolesc Psychiatry; 2023 Nov; 62(11):1170-1171. PubMed ID: 37543081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parent training for the treatment of irritability in children and adolescents: a multisite randomized controlled, 3-parallel-group, evaluator-blinded, superiority trial.
    Fongaro E; Picot MC; Stringaris A; Belloc C; Verissimo AS; Franc N; Purper-Ouakil D
    BMC Psychol; 2022 Nov; 10(1):273. PubMed ID: 36414963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design Study.
    Gordon HA; Rucklidge JJ; Blampied NM; Johnstone JM
    J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):783-98. PubMed ID: 26682999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we predict treatment response in children with ADHD to a vitamin-mineral supplement? An investigation into pre-treatment nutrient serum levels, MTHFR status, clinical correlates and demographic variables.
    Rucklidge JJ; Eggleston MJF; Darling KA; Stevens AJ; Kennedy MA; Frampton CM
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():181-192. PubMed ID: 30217770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruptive Mood Dysregulation Disorder Symptoms and Association with Oppositional Defiant and Other Disorders in a General Population Child Sample.
    Mayes SD; Waxmonsky JD; Calhoun SL; Bixler EO
    J Child Adolesc Psychopharmacol; 2016 Mar; 26(2):101-6. PubMed ID: 26745442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irritability in ADHD: Associations with depression liability.
    Eyre O; Langley K; Stringaris A; Leibenluft E; Collishaw S; Thapar A
    J Affect Disord; 2017 Jun; 215():281-287. PubMed ID: 28363151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA).
    Fernández de la Cruz L; Simonoff E; McGough JJ; Halperin JM; Arnold LE; Stringaris A
    J Am Acad Child Adolesc Psychiatry; 2015 Jan; 54(1):62-70.e3. PubMed ID: 25524791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderators of treatment response in adults with ADHD treated with a vitamin-mineral supplement.
    Rucklidge JJ; Johnstone J; Gorman B; Boggis A; Frampton CM
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Apr; 50():163-71. PubMed ID: 24374068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Across-subjects multiple baseline trial of exposure-based cognitive-behavioral therapy for severe irritability: a study protocol.
    Naim R; Kircanski K; Gold A; German RE; Davis M; Perlstein S; Clayton M; Revzina O; Brotman MA
    BMJ Open; 2021 Mar; 11(3):e039169. PubMed ID: 33692176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.